# Lantheus Holdings, Inc.: financial statements, quarterly

LNTH · Nasdaq · CIK 1521036 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lnth.md) · [Financials](/companies/lnth/financials.md) · [Filings](/companies/lnth/filings.md) · [Insiders](/companies/lnth/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lnth/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [320](/filings/0001628280-24-045459.md) | [354 d](/filings/0001193125-26-073498.md) | [370](/filings/0001628280-25-022872.md) | [394](/filings/0000950170-25-103544.md) | [379](/filings/0001193125-25-268113.md) | [391 d](/filings/0001193125-26-073498.md) | [373](/filings/0001193125-26-210373.md) | [378](/filings/0001193125-26-336795.md) | [384](/filings/0001193125-25-268113.md) | [407 d](/filings/0001193125-26-073498.md) | [377](/filings/0001193125-26-210373.md) | [388](/filings/0001193125-26-336795.md) |
| Cost of revenue | $m | [120](/filings/0001628280-24-045459.md) | [124 d](/filings/0001193125-26-073498.md) | [128](/filings/0001628280-25-022872.md) | [138](/filings/0000950170-25-103544.md) | [137](/filings/0001193125-25-268113.md) | [143 d](/filings/0001193125-26-073498.md) | [135](/filings/0001193125-26-210373.md) | [137](/filings/0001193125-26-336795.md) | [162](/filings/0001193125-25-268113.md) | [166 d](/filings/0001193125-26-073498.md) | [146](/filings/0001193125-26-210373.md) | [146](/filings/0001193125-26-336795.md) |
| Gross profit | $m | [200](/filings/0001628280-24-045459.md) | [230 d](/filings/0001193125-26-073498.md) | [242](/filings/0001628280-25-022872.md) | [256](/filings/0000950170-25-103544.md) | [242](/filings/0001193125-25-268113.md) | [249 d](/filings/0001193125-26-073498.md) | [238](/filings/0001193125-26-210373.md) | [241](/filings/0001193125-26-336795.md) | [222](/filings/0001193125-25-268113.md) | [241 d](/filings/0001193125-26-073498.md) | [231](/filings/0001193125-26-210373.md) | [242](/filings/0001193125-26-336795.md) |
| Research and development | $m | [14.5](/filings/0001628280-24-045459.md) | [16.8 d](/filings/0001193125-26-073498.md) | [48.0](/filings/0001628280-25-022872.md) | [60.6](/filings/0000950170-25-103544.md) | [24.1](/filings/0001193125-25-268113.md) | [35.3 d](/filings/0001193125-26-073498.md) | [36.3](/filings/0001193125-26-210373.md) | [45.5](/filings/0001193125-26-336795.md) | [48.0](/filings/0001193125-25-268113.md) | [47.5 d](/filings/0001193125-26-073498.md) | [39.4](/filings/0001193125-26-210373.md) | [38.2](/filings/0001193125-26-336795.md) |
| Operating income | $m | [112](/filings/0001628280-24-045459.md) | [137 d](/filings/0001193125-26-073498.md) | [107](/filings/0001628280-25-022872.md) | [103](/filings/0000950170-25-103544.md) | [134](/filings/0001193125-25-268113.md) | [114 d](/filings/0001193125-26-073498.md) | [102](/filings/0001193125-26-210373.md) | [88.0](/filings/0001193125-26-336795.md) | [43.6](/filings/0001193125-25-268113.md) | [77.2 d](/filings/0001193125-26-073498.md) | [81.3](/filings/0001193125-26-210373.md) | [100](/filings/0001193125-26-336795.md) |
| Interest expense | $m | [5.1](/filings/0001628280-23-036214.md) | [5.0 d](/filings/0001628280-24-006158.md) | [4.9](/filings/0001628280-24-019798.md) | [4.9](/filings/0000950170-25-103544.md) | [4.9](/filings/0001193125-25-268113.md) | [5.0 d](/filings/0001193125-26-073498.md) | [4.8](/filings/0001193125-26-210373.md) | [4.9](/filings/0001193125-26-336795.md) | [5.0](/filings/0001193125-25-268113.md) | [5.1 d](/filings/0001193125-26-073498.md) | [4.9](/filings/0001193125-26-210373.md) | [4.9](/filings/0001193125-26-336795.md) |
| Income tax | $m | [28.0](/filings/0001628280-24-045459.md) | [35.0 d](/filings/0001193125-26-073498.md) | [40.2](/filings/0001628280-25-022872.md) | [22.3](/filings/0000950170-25-103544.md) | [45.0](/filings/0001193125-25-268113.md) | [11.0 d](/filings/0001193125-26-073498.md) | [23.6](/filings/0001193125-26-210373.md) | [25.8](/filings/0001193125-26-336795.md) | [14.6](/filings/0001193125-25-268113.md) | [16.3 d](/filings/0001193125-26-073498.md) | [38.0](/filings/0001193125-26-210373.md) | [18.8](/filings/0001193125-26-336795.md) |
| Net income | $m | [132](/filings/0001628280-24-045459.md) | [103 d](/filings/0001193125-26-073498.md) | [131](/filings/0001193125-25-268113.md) | [62.1](/filings/0001193125-25-268113.md) | [131](/filings/0001193125-25-268113.md) | [(11.8) d](/filings/0001193125-26-073498.md) | [72.9](/filings/0001193125-26-336795.md) | [78.8](/filings/0001193125-26-336795.md) | [27.8](/filings/0001193125-25-268113.md) | [54.1 d](/filings/0001193125-26-073498.md) | [118](/filings/0001193125-26-336795.md) | [75.0](/filings/0001193125-26-336795.md) |
| Diluted EPS | $ per share | [1.88](/filings/0001628280-24-045459.md) | not reported | [1.87](/filings/0001628280-25-022872.md) | [0.88](/filings/0000950170-25-103544.md) | [1.79](/filings/0001193125-25-268113.md) | not reported | [1.02](/filings/0001193125-26-210373.md) | [1.12](/filings/0001193125-26-336795.md) | [0.41](/filings/0001193125-25-268113.md) | not reported | [1.80](/filings/0001193125-26-210373.md) | [1.11](/filings/0001193125-26-336795.md) |
| Basic EPS | $ per share | [1.93](/filings/0001628280-24-045459.md) | not reported | [1.91](/filings/0001628280-25-022872.md) | [0.89](/filings/0000950170-25-103544.md) | [1.89](/filings/0001193125-25-268113.md) | not reported | [1.06](/filings/0001193125-26-210373.md) | [1.15](/filings/0001193125-26-336795.md) | [0.41](/filings/0001193125-25-268113.md) | not reported | [1.83](/filings/0001193125-26-210373.md) | [1.15](/filings/0001193125-26-336795.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [614](/filings/0001628280-24-045459.md) | [714](/filings/0001193125-26-073498.md) | [718](/filings/0001628280-25-022872.md) | [757](/filings/0000950170-25-103544.md) | [866](/filings/0001193125-25-268113.md) | [913](/filings/0001193125-26-073498.md) | [939](/filings/0001193125-26-210373.md) | [696](/filings/0001193125-26-336795.md) | [382](/filings/0001193125-25-268113.md) | [359](/filings/0001193125-26-336795.md) | [499](/filings/0001193125-26-210373.md) | [593](/filings/0001193125-26-336795.md) |
| Current assets | $m | [948](/filings/0001628280-23-036214.md) | [1,086](/filings/0001628280-25-007970.md) | [1,149](/filings/0001628280-24-019798.md) | [1,231](/filings/0001628280-24-033630.md) | [1,296](/filings/0001628280-24-045459.md) | [1,327](/filings/0001193125-26-073498.md) | [1,424](/filings/0001628280-25-022872.md) | [1,202](/filings/0000950170-25-103544.md) | [925](/filings/0001193125-25-268113.md) | [900](/filings/0001193125-26-336795.md) | [942](/filings/0001193125-26-210373.md) | [1,027](/filings/0001193125-26-336795.md) |
| Total assets | $m | [1,522](/filings/0001628280-23-036214.md) | [1,651](/filings/0001628280-25-007970.md) | [1,831](/filings/0001628280-24-019798.md) | [1,940](/filings/0001628280-24-033630.md) | [2,050](/filings/0001628280-24-045459.md) | [1,980](/filings/0001193125-26-073498.md) | [2,055](/filings/0001628280-25-022872.md) | [2,116](/filings/0000950170-25-103544.md) | [2,276](/filings/0001193125-25-268113.md) | [2,227](/filings/0001193125-26-336795.md) | [2,347](/filings/0001193125-26-210373.md) | [2,415](/filings/0001193125-26-336795.md) |
| Current liabilities | $m | [177](/filings/0001628280-23-036214.md) | [187](/filings/0001628280-25-007970.md) | [237](/filings/0001628280-24-019798.md) | [263](/filings/0001628280-24-033630.md) | [784](/filings/0001628280-24-045459.md) | [241](/filings/0001193125-26-073498.md) | [248](/filings/0001628280-25-022872.md) | [280](/filings/0000950170-25-103544.md) | [347](/filings/0001193125-25-268113.md) | [333](/filings/0001193125-26-336795.md) | [333](/filings/0001193125-26-210373.md) | [336](/filings/0001193125-26-336795.md) |
| Total liabilities | $m | [823](/filings/0001628280-23-036214.md) | [835](/filings/0001628280-25-007970.md) | [886](/filings/0001628280-24-019798.md) | [913](/filings/0001628280-24-033630.md) | [870](/filings/0001628280-24-045459.md) | [892](/filings/0001193125-26-073498.md) | [891](/filings/0001628280-25-022872.md) | [949](/filings/0000950170-25-103544.md) | [1,157](/filings/0001193125-25-268113.md) | [1,138](/filings/0001193125-26-336795.md) | [1,134](/filings/0001193125-26-210373.md) | [1,103](/filings/0001193125-26-336795.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [0.7](/filings/0001628280-23-036214.md) | [0.8](/filings/0001628280-25-007970.md) | [0.7](/filings/0001628280-24-019798.md) | [0.9](/filings/0001628280-24-033630.md) | [565](/filings/0001628280-24-045459.md) | [1.0](/filings/0001193125-26-073498.md) | [0.7](/filings/0001628280-25-022872.md) | [0.8](/filings/0000950170-25-103544.md) | [0.9](/filings/0001193125-25-268113.md) | [0.7](/filings/0001193125-26-336795.md) | [0.8](/filings/0001193125-26-210373.md) | [0.7](/filings/0001193125-26-336795.md) |
| Shareholders' equity | $m | [699](/filings/0001628280-24-045459.md) | [816](/filings/0001193125-26-073498.md) | [946](/filings/0001193125-25-268113.md) | [1,027](/filings/0001193125-25-268113.md) | [1,180](/filings/0001193125-25-268113.md) | [1,088](/filings/0001193125-26-336795.md) | [1,164](/filings/0001193125-26-336795.md) | [1,167](/filings/0001193125-26-336795.md) | [1,119](/filings/0001193125-25-268113.md) | [1,090](/filings/0001193125-26-336795.md) | [1,212](/filings/0001193125-26-336795.md) | [1,312](/filings/0001193125-26-336795.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [117 d](/filings/0001628280-24-045459.md) | [112 d](/filings/0001193125-26-073498.md) | [127](/filings/0001628280-25-022872.md) | [84.7 d](/filings/0000950170-25-103544.md) | [175 d](/filings/0001193125-25-268113.md) | [158 d](/filings/0001193125-26-073498.md) | [108](/filings/0001193125-26-210373.md) | [87.1 d](/filings/0001193125-26-336795.md) | [105 d](/filings/0001193125-25-268113.md) | [90.2 d](/filings/0001193125-26-073498.md) | [125](/filings/0001193125-26-210373.md) | [92.2 d](/filings/0001193125-26-336795.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001628280-23-036214.md) | [0.0 d](/filings/0001628280-24-006158.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001193125-25-268113.md) | [100 d](/filings/0001193125-26-073498.md) | not reported | not reported | [100 d](/filings/0001193125-25-268113.md) | [100 d](/filings/0001193125-26-073498.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [71.1](/filings/0001628280-23-036214.md) | [67.7](/filings/0001628280-24-019798.md) | [71.0](/filings/0001628280-24-033630.md) | [70.0](/filings/0001628280-24-045459.md) | [70.1](/filings/0001628280-25-022872.md) | [70.6](/filings/0000950170-25-103544.md) | [73.1](/filings/0001193125-25-268113.md) | [71.5](/filings/0001193125-26-210373.md) | [70.3](/filings/0001193125-26-336795.md) | [67.7](/filings/0001193125-25-268113.md) | [65.8](/filings/0001193125-26-210373.md) | [67.5](/filings/0001193125-26-336795.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 65,272,369 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336795.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.